

University of Groningen

Feasibility of assessment of skeletal muscle mass on a single cross-sectional image at the level of the fourth thoracic vertebra

van Heusden, Hugo C.; Swartz, Justin E.; Chargi, Najiba; de Jong, Pim A.; van Baal, Mark C. P. M.; Wegner, Inge; de Bree, Remco

Published in:
European Journal of Radiology

DOI:
[10.1016/j.ejrad.2021.109879](https://doi.org/10.1016/j.ejrad.2021.109879)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2021

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

van Heusden, H. C., Swartz, J. E., Chargi, N., de Jong, P. A., van Baal, M. C. P. M., Wegner, I., & de Bree, R. (2021). Feasibility of assessment of skeletal muscle mass on a single cross-sectional image at the level of the fourth thoracic vertebra. *European Journal of Radiology*, 142, [109879].
<https://doi.org/10.1016/j.ejrad.2021.109879>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



Feasibility of assessment of skeletal muscle mass on a single cross-sectional image at the level of the fourth thoracic vertebra

Hugo C. van Heusden^a, Justin E. Swartz^{a,*}, Najiba Chargi^a, Pim A. de Jong^b, Mark C.P. M. van Baal^c, Inge Wegner^d, Remco de Bree^a

^a Department of Head and Neck Surgical Oncology, UMC Utrecht Cancer Center, University Medical Center Utrecht and Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands

^b Department of Radiology and Nuclear Medicine, University Medical Center Utrecht and Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands

^c Department of Surgery, University Medical Center Utrecht and Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands

^d Department of Otorhinolaryngology and Head and Neck Surgery, University Medical Center Groningen, Hanzplein 1, 9713 GZ Groningen, the Netherlands

ARTICLE INFO

Keywords:

Skeletal muscle mass
L3
Th4
Computed tomography
Sarcopenia

ABSTRACT

Background: Skeletal muscle mass (SMM) determined on computed tomography (CT) is emerging as a novel imaging biomarker. Cross-sectional area (CSA) of SMM at the level of the third lumbar vertebra (L3) on abdominal imaging is considered the clinical reference standard for measuring SMM. In certain patient groups, such as those with oncological or non-oncological lung disease like COVID-19, a chest CT may be available while an abdominal CT is not. The purpose of this study was to investigate whether determining SMM on a chest CT is a feasible alternative to abdominal CT.

Research question: What is the correlation between SMM measurements at the level of L3 and the level of the fourth thoracic vertebra (Th4)?

Study design and methods: In this study we retrospectively analyzed abdominal and thoracic series of whole-body CT-scans of trauma patients (N = 47) and head and neck cancer patients (N = 194). All abdominal muscles were delineated on a single axial slice at the level of L3. The erector spinae, levator scapulae, rhomboideus minor and major and pectoralis minor and major muscles were delineated on a single axial slice at the level of Th4. CSA of the muscles at Th4 and the L3 level were compared using linear regression, and a multivariate linear regression model was established.

Results: Muscle CSA at level Th4 strongly correlates with L3 muscle CSA ($r = 0.791$, $p < 0.05$). A multivariate model incorporating the patient characteristics arm positioning, age, sex, and weight achieved a stronger correlation ($r = 0.856$, $p < 0.05$).

Interpretation: Skeletal muscle CSA measured at the level of Th4 is a feasible alternative to measurements at L3. This allows diagnosing low SMM using clinically available thoracic CT-scans. SMM measurements at the level of Th4 may become a prognostic or triage tool when faced with mechanical ventilator shortage.

1. Introduction

Sarcopenia and low skeletal muscle mass (SMM) are important factors in patient outcome. The European Workgroup on Sarcopenia in Older People (EWGSOP) defines sarcopenia as both low SMM and low muscle function[1]. However, many studies have shown that low SMM by itself is an adverse predictive and prognostic factor for certain outcomes in patients. In cancer patients, this includes higher toxicity in patients treated with chemotherapy, more complications in surgically

treated patients and reduced survival[2–5]. Patients suffering from head and neck-cancer (HNC) are especially prone to developing low SMM, due to dysphagia caused either by the tumor and subsequent treatment or due to pre-existent risk conditions (namely poor diet, alcohol use and smoking) and low SMM is gaining ground as a predictive and prognostic biomarker in HNC-patients[6]. Additionally, low SMM has also been shown to negatively affect ventilator-free days, ICU-free days and mortality in mechanically ventilated ICU-patients[7–10].

The effect of low SMM on patient outcomes is most commonly

* Corresponding author at: University Medical Center Utrecht, mailbox Q05.4.300, Postbox 85500, 3508 GA Utrecht, the Netherlands.

E-mail address: j.e.swartz@umcutrecht.nl (J.E. Swartz).

<https://doi.org/10.1016/j.ejrad.2021.109879>

Received 8 April 2021; Received in revised form 18 June 2021; Accepted 22 July 2021

Available online 26 July 2021

0720-048X/© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

assessed using computed tomography (CT) or magnetic resonance imaging (MRI). Total body SMM can be assessed using a single axial abdominal CT-image at the level of the third lumbar vertebra (L3)[11]. In studies on the effect of SMM in patients, this method is often used and is considered a clinical reference standard. The main advantage of this method is that it can be retrospectively performed on images used for routine diagnostics and requires no additional investigations. Because imaging at the level of L3 may not be available in some patient groups, measurements at other levels have also been validated to assess SMM [12,13].

Earlier studies have used SMM at the level of the fourth thoracic vertebra (Th4) as a measurement for patients where L3 imaging is not available and correlated these measurements to outcome factors in cancer patients and non-cancer patients[14–21]. To our knowledge, there is one study analyzing the correlation between skeletal muscle cross-sectional area (CSA) at level Th4 and L3 in a cohort of patients with non-small cell lung cancer[22]. This study described only the correlation between Th4 and L3 measurements and did not include additional clinical variables to establish a prediction model for a more accurate assessment.

In the present study, we correlated the muscle CSA at the level of Th4 with L3 and established a prediction rule to accurately assess muscle CSA at the level of L3 using a chest CT.

2. Materials and methods

2.1. Patients and data

Total body CT-scans performed between 2010 and 2018 in the University Medical Center Utrecht, Utrecht, The Netherlands were randomly selected from two groups of patients. The first group underwent whole body unenhanced or contrast-enhanced CT-imaging in a trauma setting and were presumed to be otherwise healthy controls. The second group were HNC patients who underwent a whole-body (un) enhanced PET-CT scan for radiotherapy planning and disease staging. We collected age, sex, weight, and BMI when available. For HNC patients AJCC TNM staging (7th Edition) was recorded as well. These patients have been described previously in a study to validate SMM measurements at the level of C3[12].

2.2. Ethical considerations

CT-scans and other recorded patient information were coded before analysis. In accordance with Dutch “Best Practice” guidelines no informed consent or ethical approval was necessary. This study was performed under our hospital’s institutional review board approval number 17–365.

2.3. Radiological assessment

For CT-image analysis at the level of Th4 two researchers (HvH and JES) used 3D Slicer, a free open-source software application[23]. The majority (80%) of scans had a slice thickness of 0.7–1.5 mm, with the remaining percentage having a varying thickness of 1.5–4.0 mm. Slice thickness has previously been shown to slightly influence skeletal muscle area, where an increment of 3 mm results in a variance of 1%, which was deemed as an acceptable variance[24]. Image series were matched for scanning phase, i.e. in each patient the scan depicting the level of L3 was performed in the same phase as the scan at the level of Th4. Earlier research has shown that surface area measurements of muscle mass are relatively unaffected by contrast enhancement, allowing us to use both contrast enhanced and contrast unenhanced scans [25,26]. Although the noise was slightly higher in the CT scans from the PET, in our opinion this did not influence the area measurement significantly.

Both researchers segmented scans of half of all patients. Twenty

scans were randomly selected and segmented by both researchers to determine the interobserver agreement. Th4 was chosen as a reference point. Image selection was performed by scrolling in a caudad to cephalad fashion and selecting the first slice showing the head of both ribs connecting to the vertebral body of Th4. The position of each arm of the patient during the scan (upward or downward) was recorded. The researchers then manually segmented three muscle groups separately: (1) the left pectoralis minor and major muscle, (2) the right pectoralis minor and major muscle and (3) the combined bilateral muscles of the erector spinae, levator scapulae, rhomboideus minor and major, and transversospinalis groups (later referred to as ‘back muscles’). Two examples are shown in Fig. 1. Shoulder muscles were excluded due to the variation in arm positioning (upward or downward) and in some instances only partial inclusion in the field of view of the scan. These muscles were therefore deemed unreliable. SMM at the level of L3 was composed of all muscles visible at the transverse process of the third lumbar vertebra and had already been determined for these patients in a previous study[11].

After visual segmentation of the muscles, automated thresholding was performed to only include the pixels between –29 and +150 HU to prevent overestimation of muscle CSA[27]. The sum of pixels within the three segmentations were then automatically retrieved from Slicer and summed to represent the total muscle mass at the level of Th4.

2.4. Statistical analyses

The characteristics of the two patient groups were compared using independent-samples t-tests for normally distributed variables and independent-samples median tests for non-normally distributed variables. Normality was investigated using the Kolmogorov-Smirnov test. Pearson-correlation coefficients were used to determine the degree of correlation between CSA measurements. A Pearson-correlation coefficient of 0.40–0.69 was rated as moderate, a coefficient in the range of 0.70–0.89 as strong and 0.90–1.0 as very strong[28]. Interobserver agreement was determined using intraclass correlation coefficients (ICC), using a two-way mixed single measures model with absolute agreement. An ICC of less than 0.5 was indicative of poor reliability, a value between 0.5 and 0.75 as moderate, a value between 0.75 and 0.9 as good and an ICC greater than 0.90 as excellent[29].

To establish a model of the relation between Th4 and L3, missing data were handled using 10 multiple imputed data sets. Age, weight and Th4 were determined to be independent covariates. Additionally, we used age, weight, BMI and L3 as predictors for the imputation of the missing values. Multivariate linear regression was performed using the backward selection method and Akaike information criterion ($p = 0.157$) for in- and exclusion of the predictors.

A two-tailed p -value of < 0.05 was chosen as statistically significant for all other analyses. SPSS Statistics version 26.0 (IBM) was used to perform the statistical analyses. In all prediction rules value 0 was used for male sex and 1 for female sex, age was used in years, weight was used in kg and CSA in cm^2 . For arm position, two dummy variables were created. The value 1 was entered for the corresponding category (1 arm up or 2 arms up) if applicable and a 0 if this was not applicable.

3. Results

3.1. Patient characteristics

Patient characteristics are shown in Table 1. In total, 245 whole-body CT-scans were screened. Four scans were excluded from further analyses either due to impaired scan quality (for instance because of artifacts) or impacting pathology on the muscles at level Th4. We included 47 (20%) trauma patients and 194 (80%) HNC patients. There were no significant differences in sex distribution, weight, and BMI for the two groups. Weight was not recorded for 34 cases (14%) cases, and BMI could not be calculated in 36 cases (15%). HNC patients were significantly older than




Fig. 1. Example of muscle segmentation using 3D Slicer A shows a patient positioned with the left arm downwards and the right arm upwards. B shows a patient positioned with their arms upwards.

trauma patients ($p < 0.05$). There were significant differences in arm positioning between the two groups. HNC patients were routinely scanned with both arms up, where the arm positioning in trauma patients varied more often ($p < 0.05$). There was no significant effect modification between the HNC and trauma patient groups, meaning the cohort could be analyzed as a single population (p -value for interaction variable Category*Th4 muscle CSA > 0.05).

3.2. Skeletal muscle measurements

The results of the image analyses are shown in Table 2. L3 muscle CSA was not significantly different between HNC and trauma patients. All measurements at the level of Th4, bilateral pectoralis muscle CSA, back muscle CSA and CSA of the pectoralis and back muscles combined were significantly lower in the HNC patients ($p < 0.05$ corrected for age, sex and arm positioning). For HNC patients, there was no significant difference in CSA measured at the level of L3 and Th4 in patients with N0 versus N+ disease (L3: 131.9 vs 137.6 cm²; Th4: 122.8 vs 128.7 cm²) and T0-2 versus T3-4 patients (L3: 134.5 vs 136.9 cm²; Th4: 127.4 vs 125.5 cm²).

3.3. Interobserver agreement

The interobserver agreement for CSA measured at Th4 was good 0.852 (95% CI 0.633–0.941). For back muscle measurements the interobserver agreement was good as well (0.769 (0.444–0.907)). For measurements of left (0.913 (0.797–0.964)) and right (0.871 (0.707–0.947)) pectoralis muscles the interobserver agreement was excellent and good, respectively.

3.4. Correlation of L3 and Th4

The Pearson correlation coefficients for muscle mass measurements are shown in Table 3. In patients with their arms positioned upwards, the largest subgroup of patients, L3 CSA correlated strongest with the CSA of the back muscles and both pectoralis muscles followed by the CSA of the back muscles ($r = 0.805$ and $r = 0.777$ respectively). In the second largest subgroup of patients, where both arms were positioned downwards, L3 CSA had an equal measure of correlation with the CSA of the back muscles and the combined CSA of the back muscles and pectoralis muscles ($r = 0.826$). In the smallest subgroup of patients, where

Table 1
Baseline patient characteristics.

Variable	Trauma patients (n = 47)	HNC patients (n = 194)	p-value
Sex			NS
Male	30 (63.80)	134 (69.10)	
Female	17 (36.20)	60 (30.90)	
Age	54.33 (16.09)	61.64 (12.00)*	<0.05
Weight	78.77 (17.72)	72.16 (18.99)*	NS
BMI	26.12 (5.19)	24.28 (4.55)	NS
Arm positioning			<0.05
Both arms up	8 (17.0)	180 (92.78)	
One arm up	10 (21.30)	1 (0.52)	
Both arms down	29 (61.70)	13 (6.70)	
T-classification	NA		NA
T0-2		102 (52.60)	
T3-4		92 (47.40)	
N-classification	NA		NA
N0		72 (37.10)	
N+		122 (62.90)	
M-classification	NA		NA
M0		189 (97.40)	
M+		5 (2.60)	
Tumor localization	NA		NA
Oropharynx		124 (63.90)	
Other		70 (36.10)	

*Not normally distributed, shown as median (IQR).

NS: not statistically significant, NA: not applicable

Table 2
Cross-sectional area measurements.

Muscle groups	Trauma patients (n = 47)	HNC patients (n = 194)	p-value
L3	143.9 (38.6)	135.5 (30.5)	NS
Th4	154.0 (36.6)	126.5 (29.6)	<0.05
Both pectoralis muscles	49.1 (21.0)	36.9 (12.4)	<0.05
Back muscle	104.9 (22.4)	89.6 (19.2)	<0.05

All values are shown in cm² (sd). p-values are corrected for age and sex (L3 measurements) and age, sex, and arm positioning (Th4 measurements)**Table 3**
Pearson-correlation coefficients for L3 and Th4 measurements.

Patient selection	Measurement	Correlation with L3 muscle CSA (p-value)
Whole cohort (n = 241)	Pectoralis muscles	0.669 (<0.05)
	Pectoralis + back muscles	0.791 (<0.05)
	Back muscles only	0.766 (<0.05)
Both arms up (n = 188)	Pectoralis muscles	0.743 (<0.05)
	Pectoralis + back muscles	0.805 (<0.05)
	Back muscles only	0.777 (<0.05)
Both arms down (n = 42)	Pectoralis muscles	0.537 (<0.05)
	Pectoralis + back muscles	0.826 (<0.05)
	Back muscles only	0.826 (<0.05)
One arm up (n = 11)	Pectoralis muscles	0.822 (<0.05)
	Pectoralis + back muscles	0.813 (<0.05)
	Back muscles only	0.645 (<0.05)

one arm was positioned upwards, the CSA of the pectoralis muscle was strongly correlated with L3 CSA ($r = 0.822$) followed by the combined CSA of the back muscles and pectoralis muscles ($r = 0.813$). For all patients, independent of arm positioning, the strongest correlation was

between L3 CSA and the CSA of the back muscles and pectoralis muscles ($r = 0.791$). The relationship between the CSA of the skeletal muscles at level L3 and the described measurements is shown in Fig. 2.

3.5. Regression analyses

The regression analyses are shown in Table 4. Model 1 describes the prediction rules of the total Th4 muscle CSA (pectoral and back muscles combined). Model 1 (only Th4 muscle CSA) could moderately predict CSA at L3 ($r = 0.791$). In the multivariate analysis the variables age, sex, weight and BMI were introduced in model 2. BMI was excluded using backward selection. The multivariate model provided a highly accurate estimate of CSA at L3 ($r = 0.847$).

Model 3 describes the prediction rules when incorporating arm positioning. In the multivariate model the variables age, sex, weight, BMI and arm position were introduced in the model. BMI was again excluded using backward selection. This final multivariate model provides a highly accurate estimate of CSA at L3 ($r = 0.856$). As an additional analysis only in the HNC cohort, the variables T- and N-stage were added to Model 3 and did not have a significant contribution to the model ($p > 0.05$).

4. Discussion

We investigated the correlation between the CSA of muscles at the level of Th4 with the CSA of muscles at level L3. We found that there was a strong correlation between the combined CSA of all muscles measured at level Th4 and CSA at the level of L3. When one of the muscle groups was omitted (i.e., pectorales only or back muscles only) the correlation was slightly lower. We found that our multivariate prediction rule incorporating patient characteristics resulted in the most accurate assessment of muscle CSA at the level of L3. Since CSA at L3 is considered to be the clinical reference standard, our findings suggest that chest CTs can be used to predict CSA at level L3.

Patients suffering from HNC are at increased risk of developing low SMM compared to patients compared diagnosed with other types of cancer[6]. Because of this low SMM is considered an important emerging prognostic marker for these patients. While ideally whole-body CT or MR imaging is used to assess SMM, earlier research has shown that assessment using a single axial slice at the level of L3 strongly correlates to whole body SMM and is since considered the clinical reference standard[11]. This poses an issue for diseases where abdominal imaging is often unavailable, such as HNC or pulmonary disease. Previous research performed by our group has established C3 as an alternative to L3 measurements. However post-surgical or post-radiotherapeutic treatment effects may influence these measurements. In those cases measurements at the level of Th4 can be an alternative in patients with extensive localized disease or post-treatment necks.

The correlation between L3 and Th4 is stronger than reported by Grønberg et al[21]. One possible explanation may lie in the choice of muscles that were segmented. The authors reported missing muscle circumference because of the field of view from the scan. It may be that our selection of muscle groups that were segmented (back and pectorales muscles only, excluding the shoulder muscles) are less influenced by patient positioning and the scan field of view. Although the rate to which muscles were cut off from the field of view was not reported by the authors, this may have impacted their measurements. Additionally, arm positioning was not described or corrected for in the measurements of Grønberg et al. Moreover, our multivariate prediction rule incorporating patient characteristics results in a better estimation of muscle CSA at level L3.

Several points in the current study should be addressed. First, we describe a multivariate prediction rule to assess SMM in patients with thoracic CT-imaging, for instance patients with COVID-19. While SMM may be assessed in these patients using this prediction rule, it has not been validated in patients with pulmonary diseases. To broaden the




Fig. 2. Scatterplots of Th4 and L3 measurements Analysis of muscle CSA at the level of L3 and the pectorales muscles only at the level of Th4 (A), back muscles only at the level of Th4 (B), pectoralis and back muscles at the level of Th4 (C), and the estimated skeletal muscle using prediction rule 3 in Table 4.

applicability of our prediction rule, we also included a cohort of trauma patients in the study and found no significant effect modification between the two groups. However, the prediction rule should still be validated in a cohort of patients with lung diseases.

Second, especially in the trauma patient cohort the arm positioning of the patients varied. The majority of patients were scanned with arms in upward position. We found varying correlation coefficients based on arm positioning for the analyzed muscle groups. Arm positions had the greatest effect of how the pectoralis muscle was depicted, and we believe that this explains the large variance of correlation of pectoralis muscle CSA with L3 muscle CSA. Adding patient arm position to the statistical model resulted in a slightly better assessment of L3 muscle CSA and this should be taken into account when using Th4 SMM measurements. Alternatively, only the back muscle CSA at Th4 can be used although this has a slightly less strong correlation to L3 muscle CSA.

Third, weight and subsequently BMI data were missing for a minority of patients. To counteract this missing data we used multiple imputation, which has been shown to provide a more accurate assessment than a complete case analysis even with a high proportion of missing data[30,31].

Other thoracic levels have been previously investigated, such as SMM at the level of the twelfth thoracic vertebra (Th12). Ishida et al found a comparable correlation between L3 and Th12 in 161 hospitalized patients aged 65 years and older ($r = 0.858$)[32]. Matsuyama et al describe a slightly superior correlation between L3 and Th12 in 164 Japanese oral squamous cell carcinoma patients aged 40 and over ($r = 0.915$)[33]. These studies were both performed at Japanese hospitals and therefore most patients were likely of Asian ethnicity. Earlier research has shown that Asian populations have a significantly differing body composition to other ethnicities[34]. Therefore, it is not clear whether their prediction rule can be extrapolated to Caucasian patients.

Moreover, these studies did not include healthy controls in their analysis, which may have possibly skewed the results. In our study we did include trauma patients as presumed otherwise healthy controls to extrapolate our findings to other patient populations than only HNC. Ishida et al did not describe the indications for performing thoracic and abdominal imaging, therefore it is not clear whether this is a homogeneous or heterogeneous patient cohort. Finally, the median age of patients in their study was slightly higher than in our study, which could also affect measurements. Another study in 157 American patients undergoing transcatheter aortic valve replacements showed a slightly poorer correlation between L3 and Th12 ($r = 0.724$) [35]. The authors did not report on patient ethnicity. It should be noted that L3 CSA, Th4 CSA and similar measurements are all derivatives of whole-body muscle SMM. Future efforts should be made to correlate measurements on these levels to whole body SMM on CT or MRI

In conclusion, assessing SMM at level Th4 appears to be a valid method of determining total body SMM, due to the strong correlation with CSA at L3. The CSA of back and pectoralis muscles at Th4 could serve as a substitute for L3 SMM assessment when abdominal cross-sectional imaging is not available and may also be used to study the prognostic effect of SMM in cases where thoracic image is generally the only available modality, such as in COVID-19 patients.

Further prospective research should investigate the relationship between muscle mass at level Th4 in patients with pulmonary disease, such as COVID-19, and its relationship between ICU stay, ventilator free days and mortality. Moreover, our SMM prediction rule may also be relevant in establishing prediction models for ICU survival, to assess which patients have the best odds of survival in the case of an ICU shortage.

Table 4
Regression models.

Model	Covariates	Unstandardized B (95% CI)	p-value	Model R*
1. Basic prediction rule all muscles at level Th4 Prediction rule	Th4 CSA	0.78 (0.70–0.85)	<0.05	0.791
	Prediction rule CSA at L3 = 34.48 + 0.78 * Th4 CSA			
2. Backward selected multivariate model Prediction rule	Th4 CSA	0.50 (0.40–0.59)	<0.05	0.847
	Age	−0.43 (−0.68 – −0.18)	<0.05	
	Sex	−17.85 (−23.37 – −12.33)	<0.05	
	Weight	0.42 (0.25–0.60)	<0.05	
	Prediction rule CSA at L3 = 71.6 + 0.5 * Th4 CSA − 0.43 * age − 17.85 * sex + 0.42 * weight			
3. Backward selected multivariate model including arm position Prediction rule	Th4 CSA	0.55 (0.45–0.64)	<0.05	0.856
	Age	−0.45 (−0.69 – −0.21)	<0.05	
	Sex	−15.85 (−21.30 – −10.40)	<0.05	
	Weight	0.41 (0.24–0.58)	<0.05	
	1 arm up	11.02 (5.08–16.96)	<0.05	
	2 arms up	−0.55 (−12.12–11.02)	NS	
	Prediction rule CSA at L3 = 58.21 + 0.55 * Th4 CSA − 0.45 * age − 15.85 * sex + 0.41 * weight + 11.02 * 1 arm up − 0.55 * 2 arms up			

Statistical models to calculate L3 CSA based on the Th4 CSA in univariate or multivariate analysis. Pooled values from all imputed databases are shown where available. R-squared change between model 2 and 3 was significant, therefore we advise to use model 3 when applying the prediction rule.

* An R-value for the whole model is not produced from the pooled analysis. The R-value of the first imputed model is shown.

CRedit authorship contribution statement

Hugo C. van Heusden: Investigation, Software, Writing - original draft. **Justin E. Swartz:** Conceptualization, Investigation, Formal analysis, Software, Writing - original draft. **Najiba Chargini:** Investigation, Writing - review & editing. **Pim A. de Jong:** Methodology, Writing - review & editing. **Mark C.P.M. van Baal:** Investigation, Writing - review & editing. **Inge Wegner:** Methodology, Formal analysis, Validation, Writing - review & editing. **Remco de Bree:** Conceptualization, Supervision, Writing - review & editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

Guarantor of the contents: JES, RdB;

Author contributions: JES and RdB conceived the idea for this study, HvH and JES performed the measurements, JES and IW performed the analyses, all authors contributed significantly to the study design and writing of the manuscript;

Financial disclosures, sponsors, and other contributions: none.

References

- [1] A.J. Cruz-Jentoft, G. Bahat, J. Bauer, et al., Sarcopenia: Revised European consensus on definition and diagnosis, *Age Ageing* 48 (1) (2019) 16–31, <https://doi.org/10.1093/ageing/afy169>.
- [2] M.C.M. Dela Vega, A. Laviano, G.D. Pimentel, Sarcopenia and chemotherapy-mediated toxicity, *Einstein (Sao Paulo)* 14 (4) (2016) 580–584, <https://doi.org/10.1590/S1679-45082016MD3740>.
- [3] C. Simonsen, P. De Heer, E.D. Bjerre, et al., Sarcopenia and Postoperative Complication Risk in Gastrointestinal Surgical Oncology, *Ann. Surg.* 268 (1) (2018) 58–69, <https://doi.org/10.1097/SLA.0000000000002679>.
- [4] L.B.M. Weerink, A. Hoorn, B.L. Leeuwen, G.H. Bock, Low skeletal muscle mass and postoperative morbidity in surgical oncology: a systematic review and meta-analysis, *J. Cachexia Sarcopenia Muscle*. 11 (3) (2020) 636–649, <https://doi.org/10.1002/jcsm.v11.3.10.1002/jcsm.12529>.
- [5] S.S. Shachar, G.R. Williams, H.B. Muss, T.F. Nishijima, Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review, *Eur. J. Cancer* 57 (2016) 58–67, <https://doi.org/10.1016/j.ejca.2015.12.030>.
- [6] I. Almada-Correia, P.M. Neves, A. Mäkitie, et al., Body Composition Evaluation in Head and Neck Cancer Patients: A Review, *Front. Oncol.* 7 (9) (2019 Nov) 1112, <https://doi.org/10.3389/fonc.2019.01112>.
- [7] W.G.P.M. Looijaard, I.M. Dekker, S.N. Stapel, A.R.J. Girbes, J.W.R. Twisk, H. M. Oudemans-van Straaten, P.J.M. Weijs, Skeletal muscle quality as assessed by CT-derived skeletal muscle density is associated with 6-month mortality in mechanically ventilated critically ill patients, *Crit. Care* 20 (1) (2016), <https://doi.org/10.1186/s13054-016-1563-3>.
- [8] P.J.M. Weijs, W.G.P.M. Looijaard, I.M. Dekker, S.N. Stapel, A.R. Girbes, H. Straaten, A. Beishuizen, Low skeletal muscle area is a risk factor for mortality in mechanically ventilated critically ill patients, *Crit. Care* 18 (1) (2014) R12, <https://doi.org/10.1186/cc13189>.
- [9] L.L. Moisey, M. Mourtzakis, B.A. Cotton, T. Premji, D.K. Heyland, C.E. Wade, E. Bulger, R.A. Kozar, Skeletal muscle predicts ventilator-free days, ICU-free days, and mortality in elderly ICU patients, *Crit. Care* 17 (5) (2013) R206, <https://doi.org/10.1186/cc12901>.
- [10] M. Toptas, M. Yalcin, I. Akkoc, E. Demir, C. Metin, Y. Savas, M. Kalyoncuoglu, M. M. Can, The relation between sarcopenia and mortality in patients at intensive care unit, *Biomed. Res. Int.* 2018 (2018) 1–9, <https://doi.org/10.1155/2018/5263208>.
- [11] W. Shen, M. Punyanitya, Z.M. Wang, Total body skeletal muscle and adipose tissue volumes: Estimation from a single abdominal cross-sectional image, *J. Appl. Physiol.* 97 (6) (2004) 2333–2338, <https://doi.org/10.1152/jappphysiol.00744.2004>.
- [12] J.E. Swartz, A.J. Pothien, I. Wegner, E.J. Smid, K.M.A. Swart, R. de Bree, L.P. H. Leenen, W. Grolman, Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients, *Oral. Oncol.* 62 (2016) 28–33, <https://doi.org/10.1016/j.oraloncology.2016.09.006>.
- [13] B.A. Derstine, S.A. Holcombe, B.E. Ross, N.C. Wang, G.L. Su, S.C. Wang, Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population, *Sci. Rep.* 8 (1) (2018) 1–8, <https://doi.org/10.1038/s41598-018-29825-5>.
- [14] S.W. Moon, J.S. Choi, S.H. Lee, K.S. Jung, J.Y. Jung, Y.A. Kang, M.S. Park, Y. S. Kim, J. Chang, S.Y. Kim, Thoracic skeletal muscle quantification: Low muscle mass is related with worse prognosis in idiopathic pulmonary fibrosis patients, *Respir. Res.* 20 (1) (2019), <https://doi.org/10.1186/s12931-019-1001-6>.
- [15] D. Rozenberg, S. Mathur, M. Herridge, R. Goldstein, H. Schmidt, N.A. Chowdhury, P. Mendes, L.G. Singer, Thoracic muscle cross-sectional area is associated with hospital length of stay post lung transplantation: a retrospective cohort study, *Transpl. Int.* 30 (7) (2017) 713–724, <https://doi.org/10.1111/tri.2017.30.issue-710.1111/tri.12961>.
- [16] S. Mathur, N. Rodrigues, P. Mendes, D. Rozenberg, L.G. Singer, Computed Tomography-Derived Thoracic Muscle Size as an Indicator of Sarcopenia in People With Advanced Lung Disease, *Cardiopulm. Phys. Ther. J.* 28 (3) (2017) 99–105, <https://doi.org/10.1097/cpt.0000000000000054>.
- [17] J. Zuckerman, M. Ades, L. Mullie, A. Trnkus, J.F. Morin, Y. Langlois, F. Ma, M. Levental, J.A. Morais, J. Afilalo, Psoas Muscle Area and Length of Stay in Older Adults Undergoing Cardiac Operations, *Ann. Thorac. Surg.* 103 (5) (2017) 1498–1504, <https://doi.org/10.1016/j.athoracsurg.2016.09.005>.
- [18] X. Hua, J.P. Deng, Z.Q. Long, et al., Prognostic significance of the skeletal muscle index and an inflammation biomarker in patients with breast cancer who underwent postoperative adjuvant radiotherapy, *Curr. Probl. Cancer* 44 (2) (2020) 100513, <https://doi.org/10.1016/j.cupr.2019.100513>.
- [19] S. Blauwhoff-Buskermolen, J.A.E. Langius, A. Becker, H.M.W. Verheul, M.A.E. de van der Schueren, The influence of different muscle mass measurements on the diagnosis of cancer cachexia, *J. Cachexia Sarcopenia Muscle*. 8 (4) (2017) 615–622, <https://doi.org/10.1002/jcsm.12200>.
- [20] E.C.W. Neeffjes, R.M. van den Hurk, S. Blauwhoff-Buskermolen, et al., Muscle mass as a target to reduce fatigue in patients with advanced cancer, *J. Cachexia Sarcopenia Muscle*. 8 (4) (2017) 623–629, <https://doi.org/10.1002/jcsm.v8.4.10.1002/jcsm.12199>.
- [21] A. Mishra, K.D. Bigam, M. Extermann, et al., Sarcopenia and low muscle radiodensity associate with impaired FEV1 in allogeneic haematopoietic stem cell transplant recipients, *J. Cachexia Sarcopenia Muscle* 11 (6) (2020) 1570–1579, <https://doi.org/10.1002/jcsm.v11.6.10.1002/jcsm.12604>.
- [22] B.H. Grønberg, B. Sjøblom, T. Wentzel-Larsen, et al., A comparison of CT based measures of skeletal muscle mass and density from the Th4 and L3 levels in patients with advanced non-small-cell lung cancer, *Eur. J. Clin. Nutr.* 73 (7) (2019) 1069–1076, <https://doi.org/10.1038/s41430-018-0325-5>.

- [23] A. Fedorov, R. Beichel, J. Kalpathy-Cramer, et al., 3D Slicer as an image computing platform for the Quantitative Imaging Network, *Magn. Reson. Imaging* 30 (9) (2012) 1323–1341, <https://doi.org/10.1016/j.mri.2012.05.001>.
- [24] G. Fuchs, Y.R. Chretien, J. Mario, et al., Quantifying the effect of slice thickness, intravenous contrast and tube current on muscle segmentation: Implications for body composition analysis, *Eur. Radiol.* 28 (6) (2018) 2455–2463, <https://doi.org/10.1007/s00330-017-5191-3>.
- [25] A. van der Werf, I.M. Dekker, M.R. Meijerink, et al., Skeletal muscle analyses: agreement between non-contrast and contrast CT scan measurements of skeletal muscle area and mean muscle attenuation, *Clin. Physiol. Funct. Imaging* 38 (3) (2018) 366–372, <https://doi.org/10.1111/cpf.2018.38.issue-310.1111/cpf.12422>.
- [26] J.L.A. van Vugt, R.R.J. Coebergh van den Braak, H.J.W. Schippers, et al., Contrast-enhancement influences skeletal muscle density, but not skeletal muscle mass, measurements on computed tomography, *Clin. Nutr.* 37 (5) (2018) 1707–1714, <https://doi.org/10.1016/j.clnu.2017.07.007>.
- [27] S.B. Heymsfield, Z.M. Wang, R.N. Baumgartner, R. Ross, Human body composition: Advances in models and methods, *Annu. Rev. Nutr.* 17 (1) (1997) 527–558, <https://doi.org/10.1146/annurev.nutr.17.1.527>.
- [28] P. Schober, L.A. Schwarte, Correlation coefficients: Appropriate use and interpretation, *Anesth. Analg.* 126 (5) (2018) 1763–1768, <https://doi.org/10.1213/ANE.0000000000002864>.
- [29] T.K. Koo, M.Y. Li, A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research, *J. Chiropr. Med.* 15 (2) (2016) 155–163, <https://doi.org/10.1016/j.jcm.2016.02.012>.
- [30] K.J.M. Janssen, A.R.T. Donders, F.E. Harrell, et al., Missing covariate data in medical research: To impute is better than to ignore, *J. Clin. Epidemiol.* 63 (7) (2010) 721–727, <https://doi.org/10.1016/j.jclinepi.2009.12.008>.
- [31] R.H.H. Groenwold, A.R.T. Donders, K.C.B. Roes, F.E. Harrell, K.G.M. Moons, Dealing with missing outcome data in randomized trials and observational studies, *Am. J. Epidemiol.* 175 (3) (2012) 210–217, <https://doi.org/10.1093/aje/kwr302>.
- [32] Y. Ishida, K. Maeda, Y. Yamanaka, et al., Formula for the cross-sectional area of the muscles of the third lumbar vertebra level from the twelfth thoracic vertebra level slice on computed tomography, *Geriatr.* 5 (3) (2020) 47, <https://doi.org/10.3390/geriatrics5030047>.
- [33] R. Matsuyama, K. Maeda, Y. Yamanaka, Y. Ishida, R. Kato, Assessing skeletal muscle mass based on the cross-sectional area of muscles at the 12th thoracic vertebra level on computed tomography in patients with oral squamous cell carcinoma, *Oral Oncol.* 113 (2021) 105126, <https://doi.org/10.1016/j.oraloncology.2020.105126>.
- [34] T. Abe, M.G. Bembien, M. Kondo, Y. Kawakami, T. Fukunaga, Comparison of skeletal muscle mass to fat-free mass ratios among different ethnic groups, *J. Nutr. Heal Aging* 16 (6) (2012) 534–538, <https://doi.org/10.1007/s12603-012-0015-2>.
- [35] U. Nemeč, B. Heidinger, C. Sokas, L. Chu, R.L. Eisenberg, Diagnosing Sarcopenia on Thoracic Computed Tomography: Quantitative Assessment of Skeletal Muscle Mass in Patients Undergoing Transcatheter Aortic Valve Replacement, *Acad. Radiol.* 24 (9) (2017) 1154–1161, <https://doi.org/10.1016/j.acra.2017.02.008>.